AbbVie Denies Acquisition Talks with Revolution Medicines Despite WSJ Report
AbbVie denies reports of buying Revolution Medicines after Wall Street Journal claimed advanced talks.
/ 13 items
#RVMD↓
Major Biotech Upgrades and Coverage Initiations: Regeneron, Erasca, Protara, Design Therapeutics, Oric
Bank of America and Piper Sandler make bullish moves on top biotech stocks, including Regeneron, Erasca, Protara, Design Therapeutics, and Oric, highlighting growth potential, new drug updates, and pipeline opportunities.
FDA Grants Orphan Drug Status to Pancreatic Cancer Treatment Daraxonrasib
Revolution Medicines' daraxonrasib receives FDA Orphan Drug Designation for pancreatic cancer treatment, offering hope for patients with limited options in this deadly disease.
Revolution Medicines Receives FDA Priority Voucher for Cancer Drug Daraxonrasib
Revolution Medicines awarded FDA National Priority Voucher for daraxonrasib (RMC-6236), a breakthrough RAS inhibitor targeting pancreatic and lung cancer in Phase 3 trials.
Wall Street Analysts Issue Buy Ratings on Five Cancer Treatment Companies
H.C. Wainwright, Stifel, and Cantor Fitzgerald issue Buy ratings on five biotech stocks including Syndax, Black Diamond, Revolution Medicines, Verastem, and Nuvalent, citing breakthrough cancer treatments.
Erasca Stock Gets Buy Rating: Analyst Sees Huge Potential in Cancer Drug
Stifel initiates Erasca coverage with Buy rating and $4 target. Analyst sees $1.56B revenue potential for ERAS-0015 cancer treatment despite competition.